Fresenius SE (FSNUF.PK,FSNPF.PK), a German health care company, on Wednesday reported higher net income in the second quarter, while Group EBIT, a key earnings metric, and margin declined from last year, despite higher revenues.
Further, the company raised fiscal 2025 organic revenue guidance. The company now expects revenue growth between 5 percent and 7 percent, compared to previous estimate of 4 percent to 6 percent.
Constant currency EBIT growth is still expected in the range of 3 percent to 7 percent.
In fiscal 2024, revenues were 21.53 billion euros and EBIT was 2.49 billion euros.
In the second quarter, net income excluding FMC grew 6 percent to 412 million euros from last year's 388 million euros. Earnings per share excluding FMC was 0.73 euro, compared to 0.69 euro a year ago.
Group EBIT was 654 million euros, down 1 percent from 660 million euros last year, impacted by the headwinds from ceased energy relief payments at Helios Germany and the loss of the volume-based procurement tender for the nutrition product Ketosteril in China at Fresenius Kabi. Group EBIT margin was at 11.7 percent, lower than 12.2 percent a year ago.
Group revenues increased 3 percent to 5.57 billion euros from 5.41 billion euros a year ago. Revenues grew 5 percent organically, driven by consistent delivery across the core businesses Fresenius Kabi and Fresenius Helios as well as ongoing execution of #FutureFresenius. For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.